Do Not Continue Baby Aspirin – Switch to Oral Anticoagulation
In a patient with atrial fibrillation (even if currently resolved) and low bleeding risk, you should discontinue aspirin and transition from enoxaparin to a long-term oral anticoagulant (preferably a DOAC), not continue with baby aspirin. Aspirin is inadequate for stroke prevention in AF patients and adding it to anticoagulation only increases bleeding risk without additional benefit 1.
Why Aspirin Alone is Inappropriate
The 2024 ESC Guidelines explicitly state that adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for preventing ischemic stroke or thromboembolism 1. More importantly, aspirin monotherapy is simply insufficient for stroke prevention in AF:
- Oral anticoagulants reduce stroke risk by approximately 52% compared to aspirin (hazard ratio 0.48 for ischemic stroke) 2
- Recent 2026 data demonstrates that adding aspirin to DOAC therapy in AF patients significantly increases major bleeding (5.74 vs 1.37 per 100 patient-years) without reducing ischemic events 3
- Even in patients with low stroke risk, aspirin provides marginal benefit compared to anticoagulation 4
The Correct Transition Strategy
Since your patient was started on therapeutic enoxaparin and has resolved AF with low bleeding risk, here's what you should do:
Immediate Action:
- Transition from enoxaparin to a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) if available in your resource-limited setting
- If DOACs are unavailable, transition to warfarin with target INR 2.0-3.0 1
- Stop aspirin entirely – it provides no additional stroke protection and only increases bleeding risk 1, 3
Why "Resolved" AF Still Requires Anticoagulation:
The fact that AF has resolved is irrelevant to anticoagulation decisions. The 2024 ESC Guidelines recommend that oral anticoagulation continue long-term in patients with thromboembolic risk factors irrespective of whether sinus rhythm is achieved 1. The stroke risk persists even when the heart is in normal rhythm.
Resource-Limited Setting Considerations
Given your limited resources:
- First choice: Generic DOAC if available (often more cost-effective long-term than monitoring warfarin)
- Second choice: Warfarin with INR monitoring every 4 weeks once stable (target INR 2.0-3.0)
- Never acceptable: Aspirin monotherapy for AF stroke prevention
The 2021 ACC guidelines confirm that for patients requiring anticoagulation who develop conditions necessitating antithrombotic therapy, the appropriate management is nearly always to stop antiplatelet therapy and continue anticoagulation alone 5.
Common Pitfall to Avoid
Do not be tempted to use aspirin because it seems "safer" or more affordable. The evidence is unequivocal: treating 1000 AF patients for 1 year with oral anticoagulation rather than aspirin prevents 23 ischemic strokes while causing only 9 additional major bleeds 2. The net clinical benefit strongly favors anticoagulation, and aspirin creates a false sense of protection while leaving patients vulnerable to devastating strokes.
Your patient needs lifelong oral anticoagulation based on their AF diagnosis and stroke risk factors, regardless of current rhythm status 1, 6.